Salk Institute for Biological Studies-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013314)
◆英語タイトル:Salk Institute for Biological Studies - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013314
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise molecular biology and genetics, neurosciences, and plant biology. Its research provides development of new therapies and treatments for diseases such as cancer, AIDS, Alzheimer’s disease, cardiovascular disorders, anomalies of brain, birth defects, diabetes and metabolism, gene therapy, plant biology, vision, and williams syndrome, among others. Salk offers education outreach programs that delivers research impact on human health. The institute has neuroscience, molecular and cellular biology laboratories. Salk is headquartered in La Jolla, California, the US.

Salk Institute for Biological Studies – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 10
Ipsen Extends Research Agreement With Salk Institute for Biological Studies 11
Licensing Agreements 12
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies – Key Competitors 15
Salk Institute for Biological Studies – Key Employees 16
Salk Institute for Biological Studies – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Government and Public Interest 18
Sep 19, 2017: CPRIT awards $34M to UTSW for cancer research recruitment 18
May 30, 2017: Brain’s immune cells linked to Alzheimer’s, Parkinson’s, schizophrenia 20
Feb 14, 2017: Salk scientist awarded inaugural Sjoberg Prize for cancer breakthrough 22
Nov 21, 2016: Salk Institute awarded $25 million grant from Helmsley Charitable Trust 23
Aug 25, 2016: Elevating brain protein allays symptoms of Alzheimer’s and improves memory 24
Jun 27, 2016: Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells 25
Mar 28, 2016: TSRI, Salk Scientists Discover ‘Outlier’ Enzymes that Could Offer New Targets to Treat Diabetes, Inflammation 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Key Facts 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Salk Institute for Biological Studies, Deals By Therapy Area, 2011 to YTD 2017 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 10
Ipsen Extends Research Agreement With Salk Institute for Biological Studies 11
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies, Key Competitors 15
Salk Institute for Biological Studies, Key Employees 16

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Salk Institute for Biological Studies-製薬・医療分野:企業M&A・提携分析(Salk Institute for Biological Studies - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆